Please assess the completion status of the following clinical trial:

Trial Title: Albumin Replacement Therapy in Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The presence of septic shock meeting all of the following criteria:~  * Clinically possible or probable or microbiologically confirmed infection taking into account the definitions of the International Sepsis Forum (ISF)~ * Despite adequate volume therapy, vasopressors are required to maintain mean arterial pressure (MAP) ≥ 65 mm Hg for at least 1 hour~ * Serum lactate level \> 2 mmol/l (18 mg/dl) despite adequate volume therapy~* Start of septic shock less than 24 hours prior to inclusion, so that the start dose of the trial drug in the albumin group will be possible within 6-24 hours after the start of the septic shock~* Age: ≥ 18 years~* Written informed consent of the patient or his/her legal representative or confirmation of the urgency of participation in the clinical trial and possible benefit to the patient by an independent consultant or the implementation of other established procedures according to the local regulations of the contributing centre to include patients who are unable to provide informed consent in whom subsequent consent may be obtained retrospectively.~* Patients of childbearing age: negative pregnancy test~Exclusion Criteria:~* Moribund conditions with life expectancy less than 28 days because of comorbid conditions or advanced malignant disease and palliative situations with life expectancy less than 6 months~* Presence of an end of life decision prior to obtaining informed consent: Do Not Resuscitate (DNR) and Withhold/Withdraw Life-Sustaining measures~* Previous participation in this study~* Participation in another interventional clinical trial within the past 3 months~* Shock states that can be explained by other causes, e.g. cardiogenic shock, anaphylactic shock, neurogenic shock~* History of hypersensitivity to albumin or any other component of the trial drug, e.g., B., sodium caprylate, sodium N-acetyltryptophanate~* Diseases in which albumin administration may be deleterious, e.g., decompensated heart failure or traumatic brain injury~* Clinical conditions where albumin administration is indicated, e.g., hepatorenal syndrome, nephrosis, burns, intestinal malabsorption syndrome~* Lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albumin group (Type: EXPERIMENTAL): Patients assigned to the Albumin group will receive a 60 g loading dose of human albumin 20% over 2-3 hours. Serum albumin levels will be maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion.
- Control group without albumin: (Type: NO_INTERVENTION): The control group will be treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock.

Based on this trial design, predict the completion outcome and termination type (if applicable).